ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB Press release LEIDEN, the Netherlands, April 30, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. April 30, 2018
ProQR Announces Annual Meeting of Shareholders Press release LEIDEN, the Netherlands, April 11, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. April 11, 2018
ProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology Press release Key Updates April 10, 2018
ProQR to Present at Two Upcoming Conferences Press release LEIDEN, the Netherlands, April 03, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. April 03, 2018
ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis Press release Key updates September 25, 2017
ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA Press release Key Updates September 05, 2017
ProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial Press release Key Updates August 29, 2017
ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome Press release Key updates May 01, 2017